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Cellular disease models are useful tools for Alzheimer's disease (AD) research. Pluripotent stem cells,
including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), are promising
materials for creating cellular models of such diseases. In the present study, we established cellular
models of AD in hESCs that overexpressed the mutant Presenilin 1 (PS1) gene with the use of a site-
speciﬁc gene integration system. The overexpression of PS1 did not affect the undifferentiated status
or the neural differentiation ability of the hESCs. We found increases in the ratios of amyloid-b 42 (Ab42)/
Ab40 and Ab43/Ab40. Furthermore, synaptic dysfunction was observed in a cellular model of AD that
overexpressed mutant PS1. These results suggest that the AD phenotypes, in particular, the electro-
physiological abnormality of the synapses in our AD models might be useful for AD research and drug
discovery.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) is one of the most common types of
progressive dementia in the elderly population. It is characterized
by some key features, including the deposition of amyloid beta (Ab)
peptide plaques, the formation of neuroﬁbrillary tangles and the
loss of neurons [1,2]. According to the amyloid cascade hypothesis,
the extracellular accumulation of Ab peptides acts as a trigger for
the onset of AD; this is followed by changes in the presynaptic
proteins and the loss of synapses in the AD patient's brain [3e5].ll; hESC, human embryonic
ell; AD, Alzheimer's disease;
ic lateral sclerosis; SOD1, su-
ribosyltransferase 1.
ell-Material Sciences (WPI-
Sakyo-ku, Kyoto 606-8501,
a).
gawa 222-0033, Japan.
Inc. This is an open access article uCognitive ability is thought to be dependent on the synapse func-
tion of the neurons [6].
AD is classiﬁed into sporadic and familial types [7]. Presenilin 1
(PS1) is one of the genes responsible for familial AD [7,8]. PS1 is a
catalytic core of g-secretase and is produced from amyloid pre-
cursor protein by Ab species such as Ab40, Ab42 and Ab43 [9,10].
Mutant PS1 transgenic mice show some of the phenotypes of AD,
including an increased level of Ab42 and age-related neuronal loss
[11,12].
In spite of the huge efforts of researchers, there are currently no
fundamental therapeutic agents for AD. At present, pluripotent
stem cells (PSCs) such as human embryonic stem cells (hESCs) and
induced pluripotent stem cells (hiPSCs) are becoming promising
materials for basic research and cell-based therapies. PSCs are self-
renewing cells which have the ability to differentiate into any type
of cell in the human body. This ability has led to hPSC-derived
cellular disease models which can be an unlimited source for
numerous types of cells for disease research and pharmacological
studies [13e15].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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technology. Several studies have reported the establishment of
various AD patient-speciﬁc iPSC lines and AD phenotypes, in
models of AD (reviewed in Ref. [16]). However, models which
replicate the electrophysiological abnormalities of synapses have
not yet been reported. Moreover, it is difﬁcult to accurately
compare patient-speciﬁc iPSCs with healthy cells because of their
different genomic backgrounds. Isogenic iPSC lines can be gener-
ated with the use of genome-editing methods [17,18]. However, the
creation of multiple isogenic iPSC lines with this technology is
time-consuming and not cost-effective.
Recently, we developed a site-directed gene integration system
[19]. Using this system, we have already established hESC lines
which overexpress superoxide dismutase 1 (SOD1), a gene which is
responsible for amyotrophic lateral sclerosis (ALS), and showed
that our ALS models, which had different mutations, displayed
different drug responses [20]. In this study, we established hESC
lines which overexpressed mutant PS1 using the site-directed gene
integration system to create cellular models of AD. We found that
our AD models showed AD phonotypes, including synaptic
dysfunction.
2. Material and methods
2.1. The culture of hESCs
The procedure for maintaining the KhES-1 and KhES-1-HS hESC
lines was essentially the same as that which was previously
described [19,21]. The use of the hESC lines conformed to the
Guidelines for Derivation and Utilization of Human Embryonic
Stem Cells of the Ministry of Education, Culture, Sports, Science,
and Technology of Japan.
2.2. The establishment of hESC lines which overexpressed mutant
PS1 by the site-speciﬁc gene integration method
To establish hESC lines that overexpressed the PS1 gene, we
utilized the KhES-1-HS hESC line, which was the parent cell line for
the hypoxanthine phosphoribosyltransferase 1 (HPRT1) locus
speciﬁc-gene integration system [19]. The expression vectors for
wild-type and mutant PS1 cDNA (P117L, G378E, and D385A) were
constructed. The resulting PS1 expression vectors were introduced
into KhES-1-HS along with pEF1-Cre, as described in the previous
paper [19]. Karyotype analyses of the PS1-overexpressing clones
were carried out by Chromosome Science Lab, Inc. (Japan).
2.3. The neural differentiation of hESCs
Undifferentiated hESCs were cultured in N2B27 neural induc-
tion medium supplemented with both 100 ng/ml recombinant
mouse noggin (R&D systems) or 100 nM LDN193189 (Cellagen
Technology), and 1 mM SB431542 (SigmaeAldrich) on poly-L-lysine
(PLL)/Laminin111 (LM)-coated culture dishes. After 7e10 days, the
cell colonies were dissociated into cell clumps using collagenase
(GIBCO) and cultured in N2B27 mediumwith noggin or LDN193189
alone for the following 7e10 days. The cell colonies were enzy-
matically dissociated into cell clumps again and cultured in N2B27
induction medium. After 5e6 days, the cells were dissociated into
single cells by Accutase (Innovative Cell Technologies), and cultured
in N2B27 supplemented with 10 ng/ml of brain-derived neuro-
trophic factor, 10 ng/ml of neurotrophin-3 and 100 ng/ml of nerve
growth factor (all from NGF, R&D Systems) on PLL, LM and
ﬁbronectin-coated dishes for neural maturation. After 7 days, the
cells were treated with 1 mM Cytosine b-D-arabinofuranoside
(SigmaeAldrich).2.4. Immunocytochemistry
The cells were ﬁxed in freshly prepared 4% paraformaldehyde
and permeabilized by 0.5% Triton-X (Wako Chemicals, Japan). The
primary antibodies used in this study included polyclonal anti-
bodies against NANOG (ReproCELL), bIII-tubulin (Abcam), or
monoclonal antibodies against OCT3/4 (Santa Cruz Biotechnology),
NeuN (Chemicon), SSEA4 (Chemicon), TRA1-60 (Chemicon). Alexa
Fluor 488 and 568 goat anti-mouse immunoglobulin G, Alexa Fluor
488 goat anti-mouse immunoglobulin M, and Alexa Fluor 488 and
568 goat anti-rabbit IgG (Molecular Probes) were used as secondary
antibodies. The cells were counterstained with 4,6-diamidino-2-
phenylindole (DAPI) (SigmaeAldrich) for the visualization of all
nuclei. Images were captured under ﬂuorescence microscopy
(Olympus, Japan) and analyzed using the ImageJ software program
(NIH). The numbers of immunopositive cells were counted in four
or ﬁve random areas. Approximately 1000 DAPI-stained cells were
used to calculate the proportion of immunopositive cells.
2.5. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from undifferentiated hESCs using an
RNeasy mini kit (Qiagen) according to the manufacturer's protocol.
Total RNAwas subjected to cDNA synthesis using the SuperScript III
Reverse Transcriptase (Invitrogen). A semi-quantitative RT-PCRwas
carried out using the primers listed in Supplementary Table S1.
2.6. Immunoblotting
Protein extracts were prepared on ice in RIPA buffer (Sigma-
eAldrich) supplemented with a protease inhibitor cocktail
(PIERCE). The protein concentration was determined using a BCA
protein assay kit (PIERCE). The protein extracts were resolved on a
5e20% Tris-glycine acrylamide gel (Cosmobio, Japan) and trans-
ferred to a PVDF membrane (Bio-Rad) for immunoblotting. To
detect PS1 proteins, a polyclonal antibody against the N-terminal
region of the PS1 protein (Santa Cruz Biotechnology), horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG antibody (Cell
Signaling Technology), an ECL Plus Western Blotting Detection
System (GE Healthcare), and a LAS-3000 Bioimaging Analyzer
System (Fuji Film, Japan) were used. b-actin, which was used as a
loading control, was detected by a monoclonal antibody against b-
actin (Applied Biological Materials) and HRP-conjugated anti-
mouse IgG antibody (Cell Signaling Technology).
2.7. The enzyme-linked immunosorbent assays (ELISAs) for the
measurement of PS1 protein and amyloid beta expression levels
For the measurement of PS1 protein, PS1 was measured in the
protein extracted from cells using a Human Presenilin-1 N-Term
DuoSet ELISA Development kit (R&D Systems) according to the
manufacturer's protocol. The amounts of Ab40, 42 and 43 in the
culture media were measured using Human Amyloid b Assay Kits
(IBL, Japan) according to the manufacturer's protocol. N-[N-(3,5-
diﬂuorophenacetyl-L-alanyl)]-S-phenyglycine t-butyl ester (DAPT)
(Calbiochem) was used to inhibit g-secretase in the hESC-derived
neurons. The IC50 values were calculated using a MasterPlex
ReaderFit system (Hitachi Solutions, Japan).
2.8. Patch-clamp recordings
An electrophysiological analysis was performed using hESC-
derived neurons which were cultured for more than 2 weeks in a
maturation culture stage. An HEKA EPC10 ampliﬁer (HEKA In-
struments Inc) was used for recording data in a whole cell patch
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postsynaptic currents, an external solution (140 mM NaCl, 5 mM
KCl, 10 mM HEPES, 2 mM CaCl2, 1 mM MgCl2, and 10 mM glucose)
was adjusted to pH 7.2 with NaOH. A pipette solution (130 mM
Kaspartate, 1 mM MgCl2, 10 mM EGTA, 3 mM ATP-Mg, and 10 mM
HEPES) was adjusted to pH 7.2 with KOH. Neurons were voltage-
clamped at 60 mV or 30 mV to detect spontaneous excitatory
postsynaptic currents (EPSCs) or spontaneous inhibitory post-
synaptic currents (IPSCs), respectively. The inward and outward
current events were recorded as sEPSCs and as sIPSCs, respectively,
for 60 s.2.9. Electron microscopy
The hESC-derived neurons on the cover slips (15 mm in diam-
eter, Thermanox, Nunc) were chemically ﬁxed with 2% glutaralde-
hyde in NaHCa buffer (100 mM NaCl, 30 mM HEPES, 2 mM CaCl2,
adjusted at pH 7.4 with NaOH). The procedures that followed were
performed as described in our previous paper [22], with the
exception that the post-ﬁxed specimens were embedded in
Epon812 resin (TAAB Laboratories Equipment Ltd, UK).3. Results
3.1. The generation of PS1-overexpressing hESC lines
To establish hESCs that overexpressed wild-type or mutant PS1,
we utilized the site-directing gene integration system that we
developed in a previous study [19]. Using this system, an exogenous
gene of interest can be inserted into the HPRT1 locus. As described
in the Materials and Methods, the PS1 expression vectors (wild-
type PS1, PS1eP117L, PS1-G378E or PS1-D385A) were introduced
into the deﬁned site of the genome. The PS1 protein expression
level was examined to conﬁrm the overexpression of exogenousFig. 1. The undifferentiated status of PS1-overexpressing hESCs. (A) An immunoblot analysi
fragment was used to detect PS1 proteins. b-actin was used as an internal control. PS1-A,
respectively. The numbers indicate the clone identiﬁcation number. HS, the parental hESC lin
levels in the parental hESCs were deﬁned as 1.0. The mean ± SEM (n ¼ 3). There were no stati
(C) An RT-PCR of the PS1 gene and pluripotent-related genes. The primers are listed in Supp
the HPRT1 locus. NANOG, OCT3/4 and SOX2 were examined as markers of pluripotency. GA
markers. NANOG, OCT3/4, SSEA4 and TRA1-60 were used as undifferentiated markers of hEPS1 (Fig.1A). The bands of the full-length PS1were detected in all of
the drug-resistant clones that we tested, while the full-length
protein bands were not detected in the parent cell line KhES-1-
HS. In a dominant-negative mutant PS1-D385A (PS1-D clones), N-
terminal fragments of PS1 (which are generated by endoproteol-
ysis) were not detected by immunoblotting. Because Aspartate 385
is important for endoproteolysis [23], the PS1 proteins produced
from the expression vectors were not self-digested. These data
indicate that the PS1 proteins were overexpressed in these clones.
Furthermore an ELISA showed the overexpression of PS1 in these
clones (Fig. 1B). The ELISA also indicated that the PS1 protein
expression levels were almost the same among the clones that
expressed wild-type or mutant PS1 genes. These data were ex-
pected because all of the clones had exogenous PS1 genes in the
same site for gene integration and had an identical genetic back-
ground. On the other hand, the amount of N-terminal fragments of
PS1 proteins appeared to be different (Fig. 1A), suggesting that PS1
mutations might affect the efﬁciency of PS1 endoproteolysis.
An RT-PCR showed that PS1-overexpressing cells maintained
the expression of the pluripotent-related genes and endogenous
PS1, suggesting that PS1 overexpression did not affect the expres-
sion control of these pluripotent marker genes or the endogenous
PS1 gene (Fig. 1C). Next, we examined the expression of undiffer-
entiated cell markers by immunocytochemistry (Fig. 1D). All of the
colonies expressed pluripotent markers, suggesting that PS1 over-
expression did not affect the undifferentiated cell status. We also
examined karyotyping. Although one clone (PS1eB2) had an
abnormal karyotype, the other clones had normal karyotypes
(Supplementary Fig. S1). Taken together, these data indicated that
PS1 overexpression did not affect chromosome stability and that
the overexpression of PS1 did not affect undifferentiated status of
hESCs.s of PS1 overexpression in undifferentiated hESCs. An antibody against N-terminal PS1
-B, -C, and -D indicate wild-type, P117L, G378E, and D385A PS1-overexpressing cells,
e. (B) The PS1 protein expression levels were measured using ELISA. The PS1 expression
stically signiﬁcant differences in the expression levels of the PS1-overexpressing clones.
lementary Table S1. PSEN1, endogenous PS1, exoPS1, and exogenous PS1 expression on
PDH was used as an internal control gene. (D) Immunostaining with undifferentiated
SCs. Scale bar: 200 mm.
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Single clones from wild-type or mutant PS1-overexpressing
clones were used for further studies because there were no sig-
niﬁcant variations in the PS1 protein expression levels among any
of the mutant-PS1 clones and because all of clones had an identical
genetic background. First, we examined the neural differentiation
ability of the PS1-overexpressing hESC lines. Neural markers, NeuN
and bIII-tubulin were used to detect neurons derived from hESCs
(Fig. 2A). The morphology of PS1-overexpressing neurons did not
differ from the parental hESC-derived neurons. All of the cell lines
showed a similar degree of neural differentiation efﬁciency,
regardless of whether the hESC cells overexpressed the PS1 protein
or not (Fig. 2B). The overexpression of PS1 proteinwas conﬁrmed in
differentiated neurons (Fig. 2C). Although the amount of full-length
PS1 was decreased in comparison to undifferentiated cells, the N-
terminal fragments of PS1 were clearly detected as thicker bands
than in the parental hESC, HS. Electron microscopy demonstrated
that synapses still formed as usual among these mutant PS1-
expressing neurons (Fig. 2D). Collectively, these data indicate that
the overexpression of PS1 does not affect the ability of hESCs to
differentiate into neurons.3.3. Increases in Ab42 and Ab43 secretion from mutant PS1-
expressing neurons
Increased Ab42 is a major characteristic of AD phenotypes. We
measured the Ab42/Ab40 ratio in the culture medium of the hESC-
derived neurons by an ELISA (Fig. 3A). The Ab42 ratio was clearly
increased in mutant PS1-expressing neurons (PS1eB3 and
PS1eC2), while the wild-type and the dominant-negative PS1-Fig. 2. The neural differentiation of PS1-overexpressing hESCs. (A) The immunostaining of ne
were used as neuronal markers. DAPI (blue) was used to visualize nuclei. Scale bar: 100 mm. (
approximately 1000 DAPI-stained cells. The mean ± SEM (n ¼ 3). There were no statistica
hESCs (PS1-A2, PS1eB3, and PS1eC2). (C) An immunoblot analysis of PS1 overexpression
fragment was used to detect PS1 proteins. b-actin was used as an internal control. (D) A tran
density (arrow) was clearly observed at the site of contact between the two processes, includ
is typical of the presynapses, and another on the right displaying abundant microtubules an
axons. Scale: 200 nm.expressing neurons (PS1-A2 and PS1-D2) did not differ from the
parent cells. We also found that the amount of Ab43, one of the Ab
species, was clearly increased in PS1eC2 (G378E mutation) alone.
These data are consistent with a previous report which indicated
that the amount of Ab43 differed among PS1 mutant types [24].
Next, we examined the reactivity of our AD models to a g-sec-
retase inhibitor (DAPT). First, to accurately measure the IC50 values
of DAPT in our AD models, we determined the culture period of the
hESC-derived neurons. A three-week culture was not sufﬁcient to
perform an accurate IC50 measurement, but there was no signiﬁ-
cant difference between the 4- and 5-week cultures, which sug-
gested thatmore than 4weeks of culturewas required to accurately
determine the IC50 values of DAPT (Fig. 3C). We then calculated the
IC50 values of DAPT for wild-type and mutant PS1-expressing
neurons using culture media that was cultivated for 4 weeks.
There were no statistically signiﬁcant differences among them
(Fig. 3D), indicating that the mutant PS1-overexpressing neurons
show normal responsiveness to g-secretase inhibitors. In fact, our
AD models responded to other known g-secretase inhibitors, such
as BMS-708163 (Avagacestat), LY450139 (Semagacestat) and MK-
0752 (data not shown). These data suggest the potential use of
our AD models as tools for the AD drug screening system.3.4. The alteration of the excitatory synapse activity of mutant PS1-
expressing neurons
We next examined the electrophysiological features of our AD
models to evaluate the functional alteration in neurons. Patch
clamp analyses showed that there were no statistically signiﬁcant
differences in the action potential amplitude and frequency of PS1-
expressing neurons (Fig. 4A and 4B). However, we found thaturons derived from PS1-overexpressing hESCs. NeuN (red) and bIII-tubulin (bIII, green)
B) The ratio of NeuN-positive cells in differentiated cells. The ratio was calculated using
lly signiﬁcant differences among the parental hESCs (HS) and the PS1-overexpressing
in differentiated neurons derived from hESCs. An antibody against N-terminal PS1
smission electron micrograph of PS1eC2-derived neurons. A characteristic postsynaptic
ing one on the left displaying a cluster of synaptic vesicles and a mitochondrion, which
d a few elongated elements of smooth ER, which is typical of postsynaptic dendrites or
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Fig. 3. The analysis of Ab peptides secreted by PS-overexpressing neurons. (A, B) The ratios of Ab42/Ab40 (A) and Ab43/Ab40 (B). The amounts of Ab40, 42 and 43 in the culture
media were measured by an ELISA. The mean ± SEM (n ¼ 5). ***p < 0.001 in comparison to PS1-A2 (two-tailed Student's t-test). (C) The responsiveness of hESC-derived neurons to a
g-secretase inhibitor (DAPT). After plating the differentiated cells for 3, 4, and 5 weeks of neural maturationwith DAPT (0, 25, 50, 100, 200, 400 and 800 nM), the culture media were
harvested and the Ab40 concentration was measured. ***p < 0.001 and *p < 0.05 (two-tailed Student's t-test). There were no statistically signiﬁcant differences between the 4- and
5-week neurons. The mean ± SEM (n ¼ 3). (D) The IC50 values of DAPT for PS1-overexpressing neurons. The culture media were harvested at 4 weeks after plating for neural
maturation and the IC50 values of DAPT were calculated. There were no statistically signiﬁcant differences between the wild-type and mutant PS1-overexpressing neurons. The
mean ± SEM (n ¼ 3).
Fig. 4. The electrophysiological features of mutant PS1-expressing neurons. (A, B) The action potential (AP) amplitude (A) and AP frequency (B) of the PS1-overexpressing neurons.
They did not differ from PS1-A2 to a statistically signiﬁcant extent (two-tailed Student's t-test). The mean ± SEM (n ¼ 9; n ¼ 10 for PS1eC2). (C) Representative sEPSC data from
wild-type and mutant PS1-expressing neurons (PS1-A2 and PS1eC2). (D) The frequencies of sEPSCs and sIPSCs. *p < 0.05 in comparison to PS1-A2 (two-tailed Student's t-test). The
mean ± SEM (number).
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neurons (PS1-A2), while the frequency of spontaneous inhibitory
postsynaptic current (sIPSC) was not altered (Fig. 4C and D). These
data suggested that PS1-overexpressing neurons could show syn-
aptic alterations and that they may be useful as a cellular model of
AD.
4. Discussion
In the present study, we established cellular models of ADwhich
overexpressed mutant PS1 genes. We recently reported that the
overexpression of mutant SOD1 was useful for showing ALS phe-
notypes [25]. These ALS models were established by a random
integration method using mutant SOD1 cDNAs; hence the genetic
expression of exogenous SOD1 was suppressed in some clones
during neural differentiation [25]. However, this study showed that
the expression of exogenous PS1 in the AD models was never
silenced; although a slight reduction was observed in the hESC-
derived neurons - perhaps because of the property of the pro-
moter used in the present study.
In addition, the expression levels of exogenous PS1 were almost
the same among different clones with the same mutation. These
results suggest that the use of a site-speciﬁc gene integration sys-
tem enables a strict comparative analysis among the mutations in a
gene of interest. We found that the ratio of Ab42/Ab40 or Ab43/
Ab40, and that the amount of PS1 fragment after self-proteolysis
differed in 2 different PS1 mutations (P117L and. G378E), suggest-
ing that these differences might reﬂect the properties of PS1 mu-
tation. In addition, we recently reported that the ALS models
generated by our gene integrationmethod showed differential drug
responses depending on the SOD1 mutations [20]. Thus, it is of
interest whether different AD models show similarly mutation-
dependent drug responses.
Several papers have reported the usefulness of AD patient-
speciﬁc iPS cells in AD research (reviewed in Ref. [16]). However,
these models did not show electrophysiological abnormalities. In
contrast, our AD models showed synaptic dysfunction, indicating
that our AD model has an advantage in the study of synaptic ab-
normalities using healthy and diseased cells with an identical ge-
netic background. Future studies should address the cause of the
synaptic abnormality in our AD models. Also, like the reduction of
Ab production, the restoration of synaptic dysfunction in our AD
models might be a useful indicator in discovering drugs to treat AD.
In conclusion, our AD models which overexpress mutant PS1 are
useful tools for AD research as well as AD patient-iPSC-derived
models.
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